By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
First, the differences. BioDelivery Sciences International (BDSI), where Terry Coelho is an EVP and the CFO, is not like the companies our readers typically occupy.
Most of those are profitless biopharma enterprises bravely developing new drugs or drug devices not yet approved for marketing. BDSI is a profitable, commercial company selling two drug products but no longer discovering or developing any new ones. Rather than a head of R&D, the company has a chief commercial officer; most employees are in sales, and operations are geared to the market.